Tagged with Franc

pharma The general manager of Astellas France and president of LEEM, the French Pharmaceutical Companies Association, reveals how the pharmaceutical industry worldwide has to take into account what is a fair price for innovation, the sum of a value price, based on what you are providing for the health of a…

Pharma The President of Fefis, and the recently elected President of Medicen Paris Region, a Paris-based business cluster, talks about the need to build the future of the French health economy, not on past and current assets but to develop new ones; reveals how there is now a growing awareness of the…

Pharma The director of GEMME reveals how the French generics market is young in comparison to other European countries – where generics were on the market twenty years before they became available in France, how today the French Ministry of Health is sending a clear signal about the importance of generics…

Pharma The Chairman & CEO of DBV Technologies reveals how they have developed a new therapeutic method and new technology in the form of a patch to treat various allergies. DBV received a “breakthrough” designation from the FDA for the design which meets safety standards that no other products currently being developed do.…

Pharma The President of Cristers discusses the history of generic drugs in France and what steps can be taken to increase generics penetration, while also outlining the ‘cooperative’ business model behind Cristers’ meteoric rise – with a sixty-fold increase in turnover in less than a decade – from its creation in…

Pharma Yves Bur reveals how the motivation behind his political engagement has been to raise awareness around the importance of improving the social security system. Bur also explains why having a real public health policy is another way of combatting the increase in health spending, and how France needs to reach…

Pharma The General Manager of LEEM talks about the association’s strategy based on three key points, innovation, attractiveness and efficiency; how the Mediator affair has placed a question mark on the championing of the pharma industry as a national asset; why both France and Europe are at turning point and what…

innovation Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research industry and stresses the importance of knowledge-sharing for success.   What have been some of the most important changes made…

Afidro When we interviewed you in 2010, you mentioned that “while Colombia has had a solid transformation of the health system in a short time, being a model of success for Latin America, with 93% coverage of the population, it is time for the pharmaceutical industry to become a true player.…

ireland Mr. Mazeman, can you please begin by offering a brief overview of your career to date? I am a French pharmacist by training, with expertise in pharmacology. I have worked for Servier for my entire career. I started in the industry as a medical representative for the company. I went…

Nycomed France Nycomed lost an important patent with Pantoprazole in the middle of 2009, which has undoubtedly warranted some restructuring. What has been the impact of this loss on business in France, and how are you preparing for the future? Losing exclusivity with Pantoprazole is huge as it was 70% of our…

Bristol-Myers Squibb France BMS recently announced divesting from their facilities in Epernon and Meymac but at the same time reinforcing manufacturing in Agen. Could you speak to strategy of this restructuring within France and what it means for the future? In the larger context of the industry, we are at a crossroads where…